FCRL5 and neoplasm: In addition, treatment with two doses of mono-specific CAR-T cells or FcRH5/BCMA CAR-T cells from a different donor led to tumor regression, as evidenced by reduced tumor weights at the end of the experiment endpoint (Supplementary Fig. 11a–c).